Amy Elizabeth Eccles FRCR, MBBCHIR, Presenter: Nothing to Disclose

Amarnath Challapalli MBBS, MD, Abstract Co-Author: Nothing to Disclose

Sameer Khan MBBS, Abstract Co-Author: Nothing to Disclose

Sairah Khan, Abstract Co-Author: Nothing to Disclose

Tara Diane Barwick MBChB, Abstract Co-Author: Nothing to Disclose

Stephen Mangar MBChB, MD, Abstract Co-Author: Nothing to Disclose

Purpose of exhibit: 1. to understand the role of choline PET imaging in the multimodality pathway of prostate cancer 2. to describe the mechanism of action and technical aspects 3. to describe the physiological distribution of the tracer and pathological appearances in prostate cancer 4. to highlight the imaging pearls and pitfalls with case examples  

Who/When Post radical therapy with rising PSA where conventional imaging has failed to detect recurrent disease (CT, MRI, bone scan)  PSA velocity more important than absolute levels High risk staging with equivocal extra-prostatic disease on conventional imaging What/How Why not FDG? Tracers: C-11 choline, F-18 fluoroethyl, F-18 fluoromethyl choline Mechanism of action: Cell membrane metabolism Technical aspects Pearls and Pitfalls with case examples Intraprostatic disease multiparametric MRI best- why? Good for nodal and distant disease (non enlarged nodes, sclerotic and non sclerotic bone metastases) Not specific for prostate cancer: examples of secondary incidental malignancy and reactive nodes  

http://abstract.rsna.org/uploads/2014/14011697/14011697_11zj.pdf

Eccles, A, Challapalli, A, Khan, S, Khan, S, Barwick, T, Mangar, S, Choline PET in Prostate Cancer—Who, When, What, How: Imaging Pearls and Pitfalls.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14011697.html